Curis, Debiopharm Start Phase I Study Of Debio 0932 With Everolimus

(RTTNews) - Curis, Inc.(CRIS), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combination with everolimus, an inhibitor of mammalian target of rapamycin, in patients with advanced or metastatic renal cell carcinoma , who previously were treated with a VEGF-directed tyrosine kinase inhibitor. This study is designed to determine the safety and maximum tolerated dose. The pharmacokinetic profiles and any potential drug-drug interactions between the two agents will also be assessed.

"We are very pleased that this phase I study has kicked off and believe that the combination of our compound with everolimus can potentially further improve the outcome for patients suffering from RCC," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group.